These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36599133)

  • 1. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
    Bakhshi TJ; Way T; Muncy B; Georgel PT
    Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
    Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
    Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
    Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
    Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
    Collins HM; Abdelghany MK; Messmer M; Yue B; Deeves SE; Kindle KB; Mantelingu K; Aslam A; Winkler GS; Kundu TK; Heery DM
    BMC Cancer; 2013 Jan; 13():37. PubMed ID: 23356739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
    Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
    Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
    Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
    Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
    Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
    Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
    Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
    Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
    Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
    Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
    Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
    Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
    Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Haery L; Mussakhan S; Waxman DJ; Gilmore TD
    Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.
    Vincek AS; Patel J; Jaganathan A; Green A; Pierre-Louis V; Arora V; Rehmann J; Mezei M; Zhou MM; Ohlmeyer M; Mujtaba S
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30072621
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    García-Ramírez I; Tadros S; González-Herrero I; Martín-Lorenzo A; Rodríguez-Hernández G; Moore D; Ruiz-Roca L; Blanco O; Alonso-López D; Rivas JL; Hartert K; Duval R; Klinkebiel D; Bast M; Vose J; Lunning M; Fu K; Greiner T; Rodrigues-Lima F; Jiménez R; Criado FJG; Cenador MBG; Brindle P; Vicente-Dueñas C; Alizadeh A; Sánchez-García I; Green MR
    Blood; 2017 May; 129(19):2645-2656. PubMed ID: 28288979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma.
    Yu Z; Ding M; Cai Y; Lu T; Chen X; Zhou X; Wang X
    BMC Cancer; 2023 Oct; 23(1):934. PubMed ID: 37789275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
    Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
    Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic mechanisms of Rubinstein-Taybi syndrome.
    Park E; Kim Y; Ryu H; Kowall NW; Lee J; Ryu H
    Neuromolecular Med; 2014 Mar; 16(1):16-24. PubMed ID: 24381114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.